Lakefront Biotherapeutics (LKFT) Net Income towards Common Stockholders (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Net Income towards Common Stockholders for 13 consecutive years, with $16.5 million the latest figure, recorded in Q1 2026.

• Quarterly Net Income towards Common Stockholders rose 109.45% year-over-year to $16.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $907.2 million (up 570.22% YoY) and the FY2025 annual result came in at $365.2 million, up 333.15% from the prior year.
• Net Income towards Common Stockholders declined to $16.5 million in Q1 2026 per LKFT's latest filing, from $890.0 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for LKFT reached as high as $890.0 million in Q4 2025 and fell as low as -$235.8 million in Q4 2022.
• A 5-year average of $47.6 million and a median of $10.2 million in 2024 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders sank 295.16% — and 2025, when it jumped 2990.63%.
• Year by year, Net Income towards Common Stockholders stood at -$235.8 million in 2022, then jumped by 176.04% to $179.3 million in 2023, then plunged by 83.94% to $28.8 million in 2024, then soared by 2990.63% to $890.0 million in 2025, then sank by 98.15% to $16.5 million in 2026.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered $16.5 million, $890.0 million, and $2.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.